Compass Pathways aims to bring the first FDA-approved psilocybin treatment to market as psychedelics approach medical mainstream

Compass Pathways is a British biotech company seeking to move psychedelics from the social and scientific underground into mainstream medicine. Its central ambition is to bring what could become the first FDA-approved psilocybin treatment to market, positioning the company at the intersection of psychedelic drug development, clinical care, and pharmaceutical regulation. The supplied material provides only a brief description and does not specify the treatment indication, clinical trial results, regulatory status beyond the stated goal, or development limitations. It therefore supports identifying Compass Pathways and psilocybin as the core subjects, but not assessing the therapy's safety, efficacy, approval prospects, or commercial outlook.